EXPRESSION OF ANDROGEN AND ESTROGEN RECEPTORS IN INVASIVE BREAST CARCINOMA

Nguyễn Văn Chủ

Main Article Content

Abstract

Androgen receptor (AR) links a transcription factor that controls specific genes involved in different, sometimes opposite, cellular processes: it can stimulate or suppress both cell proliferation and apoptosis, depending on the concurrent signaling pathways activated. Purpose: To Comment on some relationships between the expression of AR, ER and molecular type, NPI, risk group and postoperative stage of breast cancer. Methods: Tumor samples of 94 breast cancer patients were stained with AR and ER IHC markers to determine the immunophenotype and to assess association with some pathological features. Results: In the HER2 molecular type, the AR-ER- group was accounted for the highest proportion (55.9%) and in the breast cancer with basal type, phenotype AR+ ER- was accounted for the most common rate of 52.9%. AR-ER- accounts for the highest incidence of bad risk breast cancer (58.8%). Both AR-ER+ and AR+ ER+ stage I breast cancer were accounted for a higher rate than stage III (40.0 vs 13.3% and 29.8 vs 21.5%, respectively). Conclusion: The AR-ER- immunophenotype is often associated with the worst pathological characteristics.

Article Details

References

1. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. (2009) 69:6131–40. doi: 10.1158/0008-5472.CAN-09-0452.
2. Vasiliou SK, Diamandis EP. Androgen receptor: a promising therapeutic target in breast cancer. Crit Rev Clin Lab Sci. (2019) 56:200–23. doi: 10.1080/10408363.2019.1575643.
3. Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol. (2012) 26:1941–52. doi: 10.1210/me.2011-1314.
4. Rahim B, O’Regan R. AR signaling in breast cancer. Cancers. (2017) 9:21. doi: 10.3390/ cancers9030021.
5. McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer. (2014) 21:T161–81. doi: 10.1530/ERC-14-0243.
6. Giovannelli P, Donato MD, Galasso G, Zazzo ED, Bilancio A, Migliaccio A. The Androgen Receptor in Breast Cancer. Front Endocrinol. 2018;9:492.
7. Anand A, Singh KR, Kumar S, Husain N, Kushwaha JK, Sonkar AA. Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy –a Prospective Clinical Study. Breast Care. 2017;12:160–164.
8. Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV. Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights. Molecules. 2020;25:358.